COMPANY
TYBR Health
Funding and NIH signals
- SEC Form D raise Raised $14.35M (Form D filed Jul 22, 2026). SEC Form D 0001835188-26-000001 (Jul 22, 2026)
Evidence (1 event)
- Jul 22, 2026 · SEC Form D 0001835188-26-000001
Name of Issuer: TYBR Health, Inc.; CIK: 1835188; Address: Houston, TX; Submission type: D; Filing date: 2026-07-22; Industry Group: Biotechnology; Date of First Sale: 2026-07-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 14354342; Federal exemptions: 06b
- Jul 22, 2026 · SEC Form D 0001835188-26-000001
Timeline
- FDA FDA 510(k) clearance: TYBR Collagen Gel — K250109, Jun 6, 2025. Applicant at approval: Tybr Health. source ↗
FDA records (last 2 years)
- FDA 510(k) clearance: TYBR Collagen Gel — K250109, Jun 6, 2025. Applicant at approval: Tybr Health. source ↗
NIH awards 3
- NIH award 1R43DK133012-01A1 FY2022: $269,911 awarded for that fiscal year; activity R43 (SBIR); PI KEANE, TIMOTHY JOSEPH; recipient as written: TYBR HEALTH, INC., HOUSTON, TX. Improving the safety and effectiveness o source ↗
- NIH award 1R43AR079966-01A1 FY2022: $256,573 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, PETER ALEXANDER; recipient as written: TYBR HEALTH, INC., HOUSTON, TX. Evaluation of extracellular matrix gel source ↗
- NIH award 1R43DK127897-01A1 FY2021: $255,991 awarded for that fiscal year; activity R43 (SBIR); PI KEANE, TIMOTHY JOSEPH; recipient as written: TYBR HEALTH, INC., HOUSTON, TX. Characterization of the Effect of an ECM source ↗
Connect
See your connections at TYBR Health on LinkedIn (search by name, results not checked)